Search Results

Your search for Pauline Funchain, MD matches 2 pages

Showing 1 - 2

By Pauline Funchain, MD / September 10, 2020

Growing Body of Evidence Supports Adjuvant Immunotherapy for Stage IV Melanoma With No Evidence of Disease

With incredibly paced approvals and clinical advancements in the systemic therapy of cutaneous melanoma, the efficacy of immunotherapy in this disease is clear. However, many important questions remain regarding timing and dosing—in other words, which drug (or drugs) makes the most sense and in...

skin cancer

immunotherapy

By Geraldine Carroll / May 10, 2020

New Guideline on Systemic Therapy for Melanoma Tackles Rapid Developments in Treatment Options

Systemic treatment of melanoma has changed rapidly since the introduction of ipilimumab in 2011. Newer therapies approved for melanoma since that time include immunotherapy, targeted therapy for mutation-bearing tumors, and injectional therapy for cutaneous or palpable lesions. ASCO has released...

Mar

Today In Oncology

Search Results

Your search for Pauline Funchain, MD matches 2 pages

Growing Body of Evidence Supports Adjuvant Immunotherapy for Stage IV Melanoma With No Evidence of Disease

New Guideline on Systemic Therapy for Melanoma Tackles Rapid Developments in Treatment Options

The Impact of a Pandemic on Mentorship in Medicine

Pyrotinib/Capecitabine vs Lapatinib/Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab

FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine

Continuous Coverage of COVID-19

FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma